Therefore, at least dysferlin exon 32 is thought to be a promising target of exon skipping therapy, although there are currently no ongoing or pending clinical trials involving AO-mediated therapy for dysferlinopathy. This evidence concerns the gene DYSF and neuromuscular disease caused by qualitative or quantitative defects of dysferlin.